Guardant Health director Meresman to leave board; governance reforms adopted

Guardant Health, Inc.

Stanley Meresman, a Class I director, will not stand for re-election at June 2022 annual meeting; no disagreement.
Board expanded from 7 to 9 directors, now includes 4 women.
Nominating Committee charter amended to oversee ESG, ethical compliance, IT healthcare regulatory compliance.
Code of Conduct updated with broader standards on conflicts, antitrust, political contributions, social media.
Committee assignments effective May 1, 2022: Audit (Meresman), Compensation (Gadde), Nominating (Clark).

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stanley Meresman

Director

GH · Guardant Health, Inc.

Filed: February 28, 2022, 6:59 PM ET

On February 22, 2022, Stanley Meresman informed Guardant Health, Inc. (the “Company”) that he will not stand for re-election to the Company’s Board of Directors (the “Board”) when his current term expires at the Company’s next Annual Meeting of Stockholders, which will take place in June 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stanley Meresman departed as Director at Guardant Health, Inc..

Action: will not stand for re-election
Role: Director

Exact text from the filing

On February 22, 2022, Stanley Meresman informed Guardant Health, Inc. (the “Company”) that he will not stand for re-election to the Company’s Board of Directors (the “Board”) when his current term expires at the Company’s next Annual Meeting of Stockholders, which will take place in June 2022.

View on SEC.gov

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-058240

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.